stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Return on assets
10x Genomics's return on assets over the twelve months to 30 September 2026 was −6.42%, down 2.0 percentage points from fiscal 2025 (−4.44%). Over the past ten years it has ranged from −181.0% (fiscal 2018) to −4.44% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Devices industry median of −17.3% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −4.44% | 14.95 |
| FY2024 | −19.4% | 6.20 |
| FY2023 | −25.6% | (9.38) |
| FY2022 | −16.2% | (10.23) |
| FY2021 | −5.98% | 64.72 |
| FY2020 | −70.7% | (62.14) |
| FY2019 | −8.56% | 172.41 |
| FY2018 | −181.0% | (162.21) |
| FY2017 | −18.8% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| PODD Insulet Corporation compare | 13.3% |
| GMED Globus Medical, Inc. compare | 10.5% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 9.99% |
| BIO Bio-Rad Laboratories, Inc. compare | 9.99% |
| PEN Penumbra, Inc. compare | 8.33% |
| HAE Haemonetics Corporation compare | 4.28% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BRKR Bruker Corporation compare | −2.73% |
| TXG 10x Genomics | −7.47% |
| Medical Devices industry median | −17.3% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement